Ashley Acheson
Concepts (231)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Substance-Related Disorders | 20 | 2020 | 595 | 4.640 |
Why?
| Impulsive Behavior | 20 | 2022 | 77 | 4.020 |
Why?
| Family Health | 10 | 2019 | 80 | 2.800 |
Why?
| Alcoholism | 12 | 2019 | 232 | 2.180 |
Why?
| Adolescent Behavior | 6 | 2020 | 101 | 2.040 |
Why?
| Risk-Taking | 8 | 2020 | 109 | 1.720 |
Why?
| Brain | 11 | 2024 | 1309 | 1.310 |
Why?
| Adolescent | 29 | 2023 | 6340 | 1.020 |
Why?
| Stress, Psychological | 8 | 2019 | 260 | 1.010 |
Why?
| Cannabis | 3 | 2019 | 145 | 1.000 |
Why?
| Attention | 5 | 2016 | 176 | 0.990 |
Why?
| Psychomotor Performance | 2 | 2015 | 130 | 0.950 |
Why?
| Memory, Short-Term | 5 | 2019 | 72 | 0.870 |
Why?
| Female | 52 | 2024 | 26329 | 0.800 |
Why?
| Male | 47 | 2024 | 25093 | 0.780 |
Why?
| Young Adult | 20 | 2022 | 3936 | 0.720 |
Why?
| Diffusion Tensor Imaging | 3 | 2022 | 92 | 0.710 |
Why?
| Hydrocortisone | 6 | 2019 | 107 | 0.660 |
Why?
| Photic Stimulation | 3 | 2024 | 60 | 0.630 |
Why?
| Humans | 52 | 2024 | 49827 | 0.610 |
Why?
| Cannabinoids | 1 | 2019 | 105 | 0.610 |
Why?
| Child of Impaired Parents | 2 | 2016 | 41 | 0.580 |
Why?
| Swine, Miniature | 3 | 2024 | 16 | 0.560 |
Why?
| Clinical Protocols | 1 | 2017 | 108 | 0.550 |
Why?
| Reward | 3 | 2011 | 109 | 0.550 |
Why?
| Longitudinal Studies | 8 | 2024 | 673 | 0.550 |
Why?
| Diffusion Magnetic Resonance Imaging | 4 | 2024 | 123 | 0.520 |
Why?
| Memory | 2 | 2014 | 114 | 0.520 |
Why?
| Motor Cortex | 1 | 2015 | 13 | 0.510 |
Why?
| Decision Making | 3 | 2014 | 262 | 0.510 |
Why?
| Corpus Striatum | 1 | 2015 | 50 | 0.510 |
Why?
| Child | 17 | 2024 | 6824 | 0.500 |
Why?
| Prosencephalon | 1 | 2014 | 12 | 0.500 |
Why?
| Antisocial Personality Disorder | 2 | 2012 | 13 | 0.500 |
Why?
| Alcohol Drinking | 4 | 2019 | 223 | 0.490 |
Why?
| Phenotype | 1 | 2017 | 727 | 0.490 |
Why?
| Behavior | 2 | 2012 | 45 | 0.490 |
Why?
| Parietal Lobe | 1 | 2014 | 26 | 0.480 |
Why?
| Adult | 20 | 2024 | 13160 | 0.470 |
Why?
| Temporal Lobe | 1 | 2014 | 70 | 0.460 |
Why?
| Predictive Value of Tests | 3 | 2019 | 904 | 0.460 |
Why?
| Gyrus Cinguli | 2 | 2014 | 30 | 0.450 |
Why?
| Cognition | 4 | 2023 | 336 | 0.410 |
Why?
| Risk Factors | 9 | 2020 | 3619 | 0.400 |
Why?
| Brain Mapping | 4 | 2015 | 234 | 0.400 |
Why?
| Analgesics, Opioid | 4 | 2024 | 532 | 0.360 |
Why?
| Family | 3 | 2017 | 169 | 0.360 |
Why?
| Choice Behavior | 1 | 2011 | 85 | 0.350 |
Why?
| Magnetic Resonance Imaging | 5 | 2024 | 1533 | 0.340 |
Why?
| Reaction Time | 3 | 2024 | 216 | 0.330 |
Why?
| Caudate Nucleus | 1 | 2008 | 14 | 0.330 |
Why?
| Gambling | 1 | 2008 | 18 | 0.320 |
Why?
| Catechol O-Methyltransferase | 2 | 2019 | 10 | 0.320 |
Why?
| Adolescent Development | 2 | 2020 | 19 | 0.320 |
Why?
| Bupropion | 1 | 2008 | 32 | 0.310 |
Why?
| Gene-Environment Interaction | 3 | 2017 | 36 | 0.310 |
Why?
| Tacrolimus Binding Proteins | 2 | 2019 | 6 | 0.310 |
Why?
| Temperament | 3 | 2017 | 21 | 0.300 |
Why?
| Dopamine Uptake Inhibitors | 1 | 2008 | 55 | 0.300 |
Why?
| Genetic Predisposition to Disease | 3 | 2015 | 510 | 0.290 |
Why?
| Sleep Deprivation | 1 | 2007 | 17 | 0.290 |
Why?
| Double-Blind Method | 6 | 2018 | 674 | 0.280 |
Why?
| Nucleus Accumbens | 1 | 2006 | 21 | 0.280 |
Why?
| Diazepam | 1 | 2006 | 17 | 0.280 |
Why?
| Oklahoma | 5 | 2015 | 22 | 0.270 |
Why?
| Ethanol | 4 | 2012 | 338 | 0.270 |
Why?
| Aspartic Acid | 2 | 2015 | 49 | 0.250 |
Why?
| Brain Injuries | 1 | 2006 | 160 | 0.250 |
Why?
| Nicotine | 1 | 2006 | 186 | 0.250 |
Why?
| Naltrexone | 3 | 2018 | 58 | 0.250 |
Why?
| Evoked Potentials, Visual | 1 | 2024 | 37 | 0.240 |
Why?
| Polymorphism, Single Nucleotide | 3 | 2017 | 485 | 0.240 |
Why?
| Child Abuse | 2 | 2019 | 136 | 0.240 |
Why?
| Child Behavior | 2 | 2017 | 105 | 0.230 |
Why?
| Life Change Events | 2 | 2014 | 35 | 0.230 |
Why?
| Child Development | 1 | 2024 | 185 | 0.210 |
Why?
| Risk Assessment | 3 | 2020 | 1262 | 0.210 |
Why?
| Models, Animal | 2 | 2024 | 233 | 0.200 |
Why?
| Psychotic Disorders | 1 | 2023 | 133 | 0.200 |
Why?
| Narcotic Antagonists | 3 | 2018 | 130 | 0.190 |
Why?
| Principal Component Analysis | 2 | 2019 | 55 | 0.190 |
Why?
| Schizophrenia | 1 | 2023 | 256 | 0.190 |
Why?
| Polymorphism, Genetic | 2 | 2019 | 181 | 0.190 |
Why?
| Heart Rate | 3 | 2019 | 292 | 0.180 |
Why?
| Reproducibility of Results | 4 | 2019 | 1188 | 0.180 |
Why?
| Vulnerable Populations | 1 | 2020 | 45 | 0.180 |
Why?
| Prospective Studies | 4 | 2024 | 2344 | 0.180 |
Why?
| Alcohol-Related Disorders | 1 | 2020 | 44 | 0.180 |
Why?
| Attention Deficit Disorder with Hyperactivity | 2 | 2016 | 173 | 0.180 |
Why?
| Psychomotor Agitation | 1 | 2020 | 51 | 0.180 |
Why?
| Disease Resistance | 1 | 2019 | 5 | 0.170 |
Why?
| Psychopharmacology | 1 | 2019 | 5 | 0.170 |
Why?
| Adult Survivors of Child Abuse | 2 | 2018 | 20 | 0.170 |
Why?
| Cerebral Cortex | 2 | 2012 | 200 | 0.170 |
Why?
| Anisotropy | 2 | 2022 | 64 | 0.170 |
Why?
| Central Nervous System Stimulants | 2 | 2016 | 213 | 0.170 |
Why?
| Psychiatric Status Rating Scales | 4 | 2015 | 319 | 0.170 |
Why?
| Behavior, Addictive | 1 | 2019 | 58 | 0.170 |
Why?
| Contraceptive Agents | 1 | 2019 | 16 | 0.170 |
Why?
| Circadian Rhythm | 1 | 2019 | 87 | 0.160 |
Why?
| Arousal | 1 | 2018 | 98 | 0.160 |
Why?
| Case-Control Studies | 3 | 2022 | 1128 | 0.160 |
Why?
| Antipsychotic Agents | 1 | 2020 | 232 | 0.160 |
Why?
| Personality Assessment | 1 | 2018 | 13 | 0.160 |
Why?
| Regression Analysis | 2 | 2019 | 395 | 0.150 |
Why?
| Animals | 9 | 2024 | 13150 | 0.150 |
Why?
| Cohort Studies | 2 | 2014 | 1422 | 0.150 |
Why?
| Stroop Test | 2 | 2014 | 10 | 0.150 |
Why?
| Adaptation, Psychological | 1 | 2018 | 223 | 0.150 |
Why?
| Pregnancy | 5 | 2024 | 2584 | 0.140 |
Why?
| Conduct Disorder | 1 | 2016 | 9 | 0.140 |
Why?
| Image Processing, Computer-Assisted | 2 | 2017 | 241 | 0.140 |
Why?
| Affect | 2 | 2008 | 99 | 0.140 |
Why?
| Smoking | 2 | 2012 | 510 | 0.140 |
Why?
| Drug Users | 1 | 2016 | 18 | 0.140 |
Why?
| Time Factors | 4 | 2012 | 2912 | 0.140 |
Why?
| Emergency Service, Hospital | 1 | 2020 | 488 | 0.140 |
Why?
| Methylphenidate | 1 | 2016 | 74 | 0.130 |
Why?
| Genotype | 4 | 2019 | 538 | 0.130 |
Why?
| Socioeconomic Factors | 1 | 2017 | 580 | 0.130 |
Why?
| Swine | 3 | 2024 | 391 | 0.130 |
Why?
| Receptors, Opioid, mu | 1 | 2015 | 46 | 0.120 |
Why?
| Signal Processing, Computer-Assisted | 1 | 2015 | 70 | 0.120 |
Why?
| Neural Pathways | 1 | 2015 | 97 | 0.120 |
Why?
| Breath Tests | 2 | 2012 | 39 | 0.120 |
Why?
| Parent-Child Relations | 1 | 2015 | 71 | 0.120 |
Why?
| Executive Function | 1 | 2015 | 75 | 0.120 |
Why?
| Psychological Tests | 1 | 2014 | 50 | 0.120 |
Why?
| Functional Neuroimaging | 1 | 2014 | 21 | 0.120 |
Why?
| Choline | 1 | 2014 | 61 | 0.120 |
Why?
| Follow-Up Studies | 2 | 2017 | 2179 | 0.120 |
Why?
| Frontal Lobe | 1 | 2014 | 48 | 0.120 |
Why?
| Cognition Disorders | 2 | 2012 | 218 | 0.120 |
Why?
| Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 47 | 0.120 |
Why?
| Prefrontal Cortex | 1 | 2014 | 82 | 0.110 |
Why?
| Risk | 1 | 2014 | 320 | 0.110 |
Why?
| Pregnancy Trimester, Third | 2 | 2024 | 65 | 0.110 |
Why?
| Drug-Seeking Behavior | 1 | 2012 | 5 | 0.110 |
Why?
| Social Adjustment | 1 | 2012 | 29 | 0.110 |
Why?
| Prenatal Exposure Delayed Effects | 2 | 2024 | 181 | 0.110 |
Why?
| Alcoholic Intoxication | 1 | 2012 | 19 | 0.100 |
Why?
| Substance Abuse Detection | 1 | 2012 | 92 | 0.100 |
Why?
| Binge Drinking | 1 | 2012 | 24 | 0.100 |
Why?
| Fetus | 2 | 2024 | 217 | 0.100 |
Why?
| Temperance | 1 | 2011 | 5 | 0.100 |
Why?
| Databases, Factual | 2 | 2012 | 664 | 0.100 |
Why?
| Gestational Age | 2 | 2024 | 417 | 0.100 |
Why?
| Intelligence Tests | 1 | 2011 | 44 | 0.100 |
Why?
| Central Nervous System Depressants | 1 | 2011 | 79 | 0.090 |
Why?
| Anxiety | 1 | 2012 | 269 | 0.090 |
Why?
| Drug Interactions | 3 | 2006 | 206 | 0.090 |
Why?
| Suicide, Attempted | 1 | 2011 | 76 | 0.090 |
Why?
| Rats, Sprague-Dawley | 4 | 2006 | 1595 | 0.090 |
Why?
| Behavior, Animal | 2 | 2006 | 182 | 0.080 |
Why?
| Middle Aged | 3 | 2008 | 11997 | 0.080 |
Why?
| Stress Disorders, Post-Traumatic | 1 | 2012 | 357 | 0.080 |
Why?
| Games, Experimental | 1 | 2007 | 10 | 0.070 |
Why?
| Saliva | 2 | 2019 | 54 | 0.070 |
Why?
| Rats | 4 | 2006 | 3300 | 0.070 |
Why?
| Dose-Response Relationship, Drug | 2 | 2008 | 1374 | 0.070 |
Why?
| United States | 1 | 2017 | 4838 | 0.070 |
Why?
| Quinolinic Acid | 1 | 2006 | 2 | 0.070 |
Why?
| Phosphopyruvate Hydratase | 1 | 2006 | 9 | 0.070 |
Why?
| Health Behavior | 1 | 2008 | 251 | 0.070 |
Why?
| Reference Values | 1 | 2007 | 310 | 0.070 |
Why?
| Probability | 1 | 2006 | 164 | 0.070 |
Why?
| Reinforcement Schedule | 1 | 2006 | 78 | 0.070 |
Why?
| Conditioning, Operant | 1 | 2006 | 116 | 0.070 |
Why?
| Neuropsychological Tests | 1 | 2007 | 351 | 0.060 |
Why?
| Indoles | 1 | 2008 | 278 | 0.060 |
Why?
| Personality Inventory | 2 | 2015 | 49 | 0.060 |
Why?
| Infant | 2 | 2024 | 3551 | 0.060 |
Why?
| Motor Activity | 1 | 2006 | 230 | 0.060 |
Why?
| Smoking Cessation | 1 | 2008 | 299 | 0.060 |
Why?
| Body Weight | 1 | 2006 | 513 | 0.060 |
Why?
| Social Environment | 1 | 2024 | 80 | 0.060 |
Why?
| Interpersonal Relations | 2 | 2016 | 102 | 0.060 |
Why?
| Sex Factors | 1 | 2006 | 693 | 0.060 |
Why?
| Comorbidity | 2 | 2017 | 618 | 0.060 |
Why?
| Morphine | 1 | 2004 | 102 | 0.060 |
Why?
| Immunohistochemistry | 1 | 2006 | 971 | 0.060 |
Why?
| Texas | 2 | 2014 | 137 | 0.060 |
Why?
| Luteinizing Hormone | 1 | 2002 | 49 | 0.050 |
Why?
| Macaca mulatta | 1 | 2002 | 92 | 0.050 |
Why?
| Buprenorphine | 1 | 2004 | 134 | 0.050 |
Why?
| Growth Hormone | 1 | 2002 | 96 | 0.050 |
Why?
| Age Factors | 2 | 2018 | 1090 | 0.050 |
Why?
| Emotions | 2 | 2012 | 165 | 0.050 |
Why?
| Controlled Clinical Trials as Topic | 1 | 2020 | 21 | 0.050 |
Why?
| Ultrasonography, Prenatal | 1 | 2022 | 188 | 0.050 |
Why?
| Injections, Intramuscular | 1 | 2020 | 54 | 0.050 |
Why?
| Speech | 1 | 2019 | 52 | 0.040 |
Why?
| Alleles | 1 | 2019 | 251 | 0.040 |
Why?
| Puberty | 1 | 2018 | 18 | 0.040 |
Why?
| Sexual Maturation | 1 | 2017 | 14 | 0.040 |
Why?
| Cross-Over Studies | 1 | 2018 | 224 | 0.040 |
Why?
| Linear Models | 1 | 2018 | 281 | 0.040 |
Why?
| Aging | 1 | 2002 | 688 | 0.040 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2020 | 553 | 0.040 |
Why?
| Southwestern United States | 1 | 2017 | 16 | 0.040 |
Why?
| Sensation | 1 | 2017 | 12 | 0.040 |
Why?
| Psychometrics | 1 | 2018 | 220 | 0.040 |
Why?
| Child, Preschool | 1 | 2024 | 3853 | 0.030 |
Why?
| Mathematical Concepts | 1 | 2015 | 2 | 0.030 |
Why?
| Social Perception | 1 | 2015 | 28 | 0.030 |
Why?
| Age of Onset | 1 | 2015 | 106 | 0.030 |
Why?
| Random Allocation | 1 | 2015 | 280 | 0.030 |
Why?
| Residence Characteristics | 1 | 2015 | 151 | 0.030 |
Why?
| Mood Disorders | 1 | 2014 | 59 | 0.030 |
Why?
| Sex Characteristics | 1 | 2015 | 190 | 0.030 |
Why?
| Mothers | 1 | 2016 | 248 | 0.030 |
Why?
| Checklist | 1 | 2012 | 28 | 0.030 |
Why?
| Sex Distribution | 1 | 2012 | 135 | 0.030 |
Why?
| Positron-Emission Tomography | 1 | 2012 | 294 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2012 | 854 | 0.020 |
Why?
| Mental Disorders | 1 | 2014 | 389 | 0.020 |
Why?
| Cross-Sectional Studies | 1 | 2014 | 1541 | 0.020 |
Why?
| Skin | 1 | 2012 | 407 | 0.020 |
Why?
| Depression | 1 | 2011 | 564 | 0.020 |
Why?
| Rats, Long-Evans | 1 | 2004 | 26 | 0.020 |
Why?
| Taste | 1 | 2004 | 33 | 0.010 |
Why?
| Species Specificity | 1 | 2004 | 193 | 0.010 |
Why?
| Administration, Oral | 1 | 2004 | 423 | 0.010 |
Why?
| Periodicity | 1 | 2002 | 24 | 0.010 |
Why?
| Growth Hormone-Releasing Hormone | 1 | 2002 | 29 | 0.010 |
Why?
| Progesterone | 1 | 2002 | 57 | 0.010 |
Why?
| Analysis of Variance | 1 | 2004 | 565 | 0.010 |
Why?
| Insulin-Like Growth Factor I | 1 | 2002 | 137 | 0.010 |
Why?
| Oligopeptides | 1 | 2002 | 89 | 0.010 |
Why?
| Estradiol | 1 | 2002 | 225 | 0.010 |
Why?
| Disease Models, Animal | 1 | 2005 | 1451 | 0.010 |
Why?
|
|
Acheson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|